Kintara Therapeutics granted extension by Nasdaq to regain compliance

Kintara Therapeutics received notice from Nasdaq that the staff has determined to grant the company an extension of time to regain compliance with the listing rule requiring a minimum $2.5M equity, $35M market value of listed securities, or $500K net income from continuing operations. The Staff granted an extension until March 18, 2024 to regain compliance with the Rule, conditioned upon the company’s achievement of certain milestones included in the plan of compliance previously submitted to the Staff. If the company fails to evidence compliance upon filing its periodic report for the quarter ending March 31, 2024 with the SEC and Nasdaq, the company may be subject to delisting. Nasdaq’s extension notice has no immediate effect on the continued listing status of the Company’s common stock on the Nasdaq Capital Market under the symbol “KTRA“.